Subcutaneous immunoglobulins: Product characteristics and their role in primary immunodeficiency disease

International Reviews of Immunology

Volumn 31, Issue 6, 2012, Pages 451-461

  Melamed, Isaac ^a   Testori, Alessandro ^a   Spirer, Zvi ^b  

^a IMMUNOe International Research Centers   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Adverse drug reactions; Immunoglobulin G; Immunologic deficiency syndrome; Intravenous immunoglobulin therapy; Primary immunodeficiency disease

Indexed keywords

GAMUNEX C; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ABSCESS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION; INFUSION RATE; INFUSION RELATED REACTION; MENINGITIS; OSTEOMYELITIS; PATIENT SATISFACTION; PRIORITY JOURNAL; SEPSIS;

ANIMALS; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; SUBCUTANEOUS TISSUE;

EID: 84870866875     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.732631     Document Type: Article

References (46)

1. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodefciency diseases in the United States. J Clin Immunol 2007;27:497-502.
2. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodefciency disease. Ter Clin Risk Manag 2010;6:1-10.
3. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-728.
4. Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002;2:368-738.
5. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980;93:55-56.
6. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009;158(Suppl 1):51-59.
7. Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991;338:162-166.
8. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2001;104:237-241.
9. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immun-odefciency. Immunol Allergy Clin North Am 2008;28:413-437.
10. Gardulf A. Immunoglobulin treatment for primary antibody defciencies: advantages of the subcutaneous route. BioDrugs 2007;21:105-116.
11. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010;30:301-307.
12. Chapel HM, Spickett GP, Ericson D, et al. Te comparison of the efcacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94-100.
13. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodefciencies. Pediatrics 1996;98:1127-1131.
14. Dams ET, van der Meer JW. Subcutaneous immunoglobulin replacement in patients with primary antibody defciencies. Lancet 1995;345:864.
15. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody defciencies: safety and costs. Lancet 1995;345:365-369.
16. Gardulf A, Bjorvell H, Gustafson R, et al. Te life situations of patients with primary antibody defciency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993;92:200-204.
17. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998;79:48-51.
18. Grunebaum E, Levy Y, Shoenfeld Y. Novel aspects of hypogammaglobulinemic states: subcutaneous immunoglobulin treatment. Isr Med Assoc J 2002;4:288-289.
19. Tomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet 342:1432-1433.
20. Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Der-matol 2004;43:163-166.
21. Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-defcient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112: 341-346.
22. Gardulf A, Bjorvell H, Gustafson R, et al. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody defciency. Immunodefciency 1993;4:81-84.
23. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28:803-819.
24. Berger M, Murphy E, Riley P, et al. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodefciency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010;103(9):856-863.
25. Berger M. Subcutaneous IgG therapy in immune defciency diseases. In: Blaese RM, editor. Clinical focus on primary immune defciencies. Towson, MD: Immune Defciency Foundation; February 2008:1-12. http://primaryimmune.org/about- primary-immunodefciency-diseases/publications. Accessed 1/11/2012.
26. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodefciency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525-S553.
27. GardulfA, NicolayU.Replacement IgG therapyand self-therapyathomeimprove the health-related quality of life in patients with primary antibody defciencies. Curr Opin Allergy Clin Immunol 2006;6:434-442.
28. Ochs HD, Gupta S, Kiessling P, et al. Safety and efcacy of self-administered subcutaneous immunoglobulin in patients with primary immunodefciency diseases. J Clin Immunol 2006;26:265-273.
29. Gustafson R, Gardulf A, Hansen S, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody defciencies. Clin Exp Immunol 2008;152:274-279.
30. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodefciency. J Clin Immunol 1994;14:90-97.
31. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody defcien-cies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114(4):936-942.
32. Gammagard liquid [immune globulin infusion (human)] 10% prescribing information. Westlake Village, CA: Baxter Healthcare Corporation, 2012.
33. Gamunex-C (immune globulin injection [human] 10% caprylate/chromatography purifed) prescribing information. Research Triangle Park, NC: Talecris Biotherapeutics, Inc., 2010.
34. Hizentra immune globulin subcutaneous (human) (IGSC), 20% liquid prescribing information. Kankakee, IL: CSL Behring LLC, 2011.
35. Vivaglobin immune globulin subcutaneous (human) 16% liquid prescribing information. Kanka-kee, IL: CSL Behring LLC, 2010.
36. Gammagard S/D [immune globulin intravenous (human)], solvent detergent treated, IgA less than 2.2 μg/mL in a 5% solution. Westlake Village, CA: Baxter Healthcare Corporation, December 2009.
37. Immune Defciency Foundation. Characteristics of immune globulin products currently licensed for use in the United States. http://primaryimmune.org/ treatment-information/immunoglobulin-products. Accessed October 2012.
38. Wasserman RL, Melamed I, Kobrynski L, et al. Efcacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodefciency disease. J Clin Immunol 2011;31:323-331.
39. WassermanRL, Irani AM, TracyJ, et al. Pharmacokinetics andsafetyof subcutaneous immune globulin (human), 10% caprylate/chromatography purifed in patients with primary immunodefciency disease. Clin Exp Immunol 2010;161:518-526.
40. Borte M, Ritchie B, Plebani A, et al. Improvement in quality of life measurements in newly diagnosed patients with primary immunodefciency receiving directly initiated subcutaneous replacement therapy with Vivaglobin. Abstract # 551. J Allergy Clin Immunol 2010;125:AB140.
41. Schif RI, Williams LW, Nelson RP, et al. Multicenter crossover comparison of the safety and ef-cacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodefciency diseases. J Clin Immunol 1997;17:21-28.
42. Melamed I, Nef A, McDonald A. Subcutaneous immunoglobulins (IGSC): product characteristics and their role in primary immunodefciency disease (PIDD). Paper presented at the Clinical Immunology Society Meeting, 12-22 May 2011; Chicago, IL, Poster presentation # 29.
43. Berger M. Choices of IgG replacement therapy for primary immune defciency diseases: subcutaneous IgG vs. intravenous IgG and optimal dose. Curr Opin allergy Clin Immunol 2011;11:32-538.
44. Stein MR, Koterba A, Rodden, et al. Safety and efcacy of home-based subcutaneous im-munoglobulin G in elderly patients with primary immunodefciency diseases. Postgrad Med 2011;123(5):186-193.
45. Kaveri SV, Maddur MS, Hegde P, et al. Intravenous immunoglobulins in immunodefciencies: more than mere replacement therapy. Clin Exp Immunol 2011;164(Suppl 2):2-5.
46. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins-understanding properties and mechanisms. Clin Exp Immunol 2009;158(Suppl 1):2-13.